On June 3rd, the House of Representatives passed the Safeguarding America’s Pharmaceuticals Act of 2013.
The bipartisan legislation would enhance the security of the pharmaceutical distribution supply chain for America’s patients while preventing duplicative federal and state requirements from being imposed on drug manufacturers, wholesale distributors, and pharmacies.
Further, the legislation would establish a collaborative, transparent process between the FDA and stakeholders in order to better understand how and when to move to unit-level traceability.
A similar bill is pending before the U.S. Senate, currently scheduled to be considered in early July. The bills would then proceed to a Conference Committee with the goal of being signed into law by the President in early August.
AstraZeneca is pleased with the passage of this legislation and supports the protection of patients from counterfeit medications.